Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib plus fulvestrant in pretreated ER+/HER2- metastatic breast cancer
2014-005387-15Phase 2Completed
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of palbociclib in breast cancer, sponsored by ETOP IBCSG Partners Foundation. Primary endpoint: Progression-free survival correlated with gene mutations. Started Sep 2015; status: completed.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2014-005387-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005387-15.